Insights from ESC: Treat Earlier, Implement Better, and Question What We Thought We Knew

In this episode of The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, reviewed clinical trials from days 2 and 3 of the European Society of Cardiology (ESC) Congress 2026 in Munich, framing them around a single message: knowing what works is not enough—clinicians must identify the right patient, intervene at the right time, and build systems that reliably deliver evidence-based care.

Across the cardiovascular continuum, Beavers walked through prevention (STAREE, REACT, and AMUNDSEN); thrombosis and antithrombotic strategy (ENRICH-AF, LIBREXIA-ACS, PREMIUM, and SWITCH SWEDEHEART); implementation science (EMAIL-HF, ADHERE-ASCVD, and TIME-HF); revisited heart failure therapies (DANHEART's H-HeFT and Met-HeFT); and structural heart disease (ACASA-TAVI). He highlighted STAREE as practice-changing: in nearly 10,000 adults aged 70 and older, atorvastatin 40 mg reduced major cardiovascular events from 8.3% to 6.0% (about a 30% relative reduction) without improving disability-free survival—meaning age alone should no longer be a reason to withhold a statin, though life expectancy and time-to-benefit must guide the decision.

Recurring themes include the following: Atherosclerosis is a lifelong disease; more therapy is not automatically better; less therapy is not automatically better; surrogates are not outcomes; and—most important for pharmacists—implementation is treatment. Beavers argued the next advance in cardiovascular medicine may come as much from delivery systems, analytics, and team-based care as from new drugs and that pharmacists are positioned to lead that work by finding and closing treatment gaps rather than waiting for patients to fall through them.